Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kronos Bio stock in Canada | $16.78

Own Kronos Bio shares in just a few minutes.

Compare brokers
Avatar
Jing Jun Ma
Updated
Fact checked

Kronos Bio Inc is a biotechnology business based in the US. Kronos Bio shares (KRON) are listed on the NASDAQ and all prices are listed in US Dollars. Kronos Bio employs 90 staff and has a market cap (total outstanding shares value) of USD$999.1 million.

How to buy shares in Kronos Bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KRON – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Kronos Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

What's in this guide?

  1. Can I buy shares in Kronos Bio?
  2. Kronos Bio shares summary
  3. Compare share dealing platforms
  4. Is Kronos Bio stock a buy or sell?
  5. Kronos Bio performance over time
  6. Can I short Kronos Bio shares?
  7. Kronos Bio's financials
  8. Does Kronos Bio pay a dividend?
  9. Other common questions

Kronos Bio stock price

Use our graph to track the performance of KRON stocks over time.

Kronos Bio shares at a glance

Information last updated 2021-10-10.
Latest market close$16.78
52-week range$17.62 - $39.61
50-day moving average $21.79
200-day moving average $23.47
Wall St. target price$42.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.16

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get 2 free stocks when you open a Wealthsimple Trade personal account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Go to site
More Info
Interactive Brokers
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Go to site
More Info
BMO InvestorLine
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.
An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Go to site
More Info
Scotia iTRADE
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Go to site
More Info
CIBC Investor's Edge
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Go to site
More Info
Questrade
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Go to site
More Info
Qtrade Direct Investing
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until December 31, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
Go to site
More Info
loading

Compare up to 4 providers

Online stock trading

Kronos Bio price performance over time

Historical closes compared with the close of $16.78 from 2021-10-15

1 week (2021-10-08) -5.52%
1 month (2021-09-17) -30.95%
3 months (2021-07-16) -18.35%
6 months (2021-04-16) -22.17%
1 year (2020-10-16) -47.66%
2 years (2019-10-13) N/A
3 years (2018-10-13) N/A
5 years (2016-10-13) N/A

Kronos Bio financials

Gross profit TTM $0
Return on assets TTM -20.52%
Return on equity TTM -50.3%
Profit margin 0%
Book value $7.75
Market capitalisation $999.1 million

TTM: trailing 12 months

Shorting Kronos Bio shares

There are currently 4.1 million Kronos Bio shares held short by investors – that's known as Kronos Bio's "short interest". This figure is 2.2% down from 4.2 million last month.

There are a few different ways that this level of interest in shorting Kronos Bio shares can be evaluated.

Kronos Bio's "short interest ratio" (SIR)

Kronos Bio's "short interest ratio" (SIR) is the quantity of Kronos Bio shares currently shorted divided by the average quantity of Kronos Bio shares traded daily (recently around 212252.43775934). Kronos Bio's SIR currently stands at 19.28. In other words for every 100,000 Kronos Bio shares traded daily on the market, roughly 19280 shares are currently held short.

However Kronos Bio's short interest can also be evaluated against the total number of Kronos Bio shares, or, against the total number of tradable Kronos Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kronos Bio's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Kronos Bio shares in existence, roughly 70 shares are currently held short) or 0.0932% of the tradable shares (for every 100,000 tradable Kronos Bio shares, roughly 93 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kronos Bio.

Kronos Bio share dividends

We're not expecting Kronos Bio to pay a dividend over the next 12 months.

Kronos Bio overview

Kronos Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Frequently asked questions

Kronos Bio in the news

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site